Azalea Therapeutics
San Francisco, US · 2 known investors
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
Founders & leadership
JD
Jennifer DoudnaCo-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley
RB
Rodolphe BarrangouCo-founder, Associate Professor of Medicine, UCSF
KR
Krishnendu RoyCo-founder, Professor of Bioengineering, Stanford University
Investors · 2
In the news
- Biopharma Startup Funding (2026) – New Market Pitchnewmarketpitch.com · 2026
- Azalea Therapeutics - 2026 Funding Rounds & List of Investors - Tracxntracxn.com · 2025
- Wilson Sonsini Advises Azalea Therapeutics on $82 Million Financing | Wilson Sonsiniwsgr.com · 2025
- Azalea Therapeutics Launches with $82M Funding to Pioneer In Vivo Cell Engineering | PackGene Biotechpackgene.com · 2025
- Jennifer Doudna biotech Azalea Therapeutics raises $82 million | STATstatnews.com · 2025
- Azalea Therapeutics Raises $82M in Series A Fundingfinsmes.com · 2025